Trevena Inc (TRVN)

$0.414

+0.01

(+1.47%)▲

Market is closed - opens 7 PM, 05 Jun 2024

Insights on Trevena Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 3.02M → -81.0K (in $), with an average decrease of 119.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -7.93M → -16.51M (in $), with an average decrease of 108.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 71.8% return, outperforming this stock by 132.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 334.2%

Performance

  • $0.39
    $0.44
    $0.41
    downward going graph

    4.88%

    Downside

    Day's Volatility :10.73%

    Upside

    6.16%

    downward going graph
  • $0.30
    $1.12
    $0.41
    downward going graph

    26.8%

    Downside

    52 Weeks Volatility :73.21%

    Upside

    63.39%

    downward going graph

Returns

PeriodTrevena IncIndex (Russel 2000)
3 Months
-30.84%
0.0%
6 Months
-31.89%
0.0%
1 Year
-60.39%
0.0%
3 Years
-99.09%
-22.6%

Highlights

Market Capitalization
7.2M
Book Value
- $0.44
Earnings Per Share (EPS)
-2.72
PEG Ratio
0.0
Wall Street Target Price
4.0
Profit Margin
0.0%
Operating Margin TTM
12374.39%
Return On Assets TTM
-49.4%
Return On Equity TTM
-1014.58%
Revenue TTM
3.1M
Revenue Per Share TTM
0.25
Quarterly Revenue Growth YOY
-70.0%
Gross Profit TTM
-3.4M
EBITDA
-35.0M
Diluted Eps TTM
-2.72
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.47
EPS Estimate Next Year
-1.37
EPS Estimate Current Quarter
-0.47
EPS Estimate Next Quarter
-0.42

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Trevena Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 866.18%

Current $0.41
Target $4.00

Technicals Summary

Sell

Neutral

Buy

Trevena Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Trevena Inc
Trevena Inc
-2.16%
-31.89%
-60.39%
-99.09%
-98.53%
Moderna, Inc.
Moderna, Inc.
19.0%
85.08%
12.75%
-28.27%
721.13%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.54%
31.88%
92.14%
229.83%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
36.12%
71.83%
234.04%
457.53%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
32.76%
40.6%
124.79%
171.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Trevena Inc
Trevena Inc
NA
NA
0.0
-1.47
-10.15
-0.49
NA
-0.44
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Trevena Inc
Trevena Inc
Buy
$7.2M
-98.53%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
721.13%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
229.83%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
457.53%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
171.36%
29.59
39.46%

Institutional Holdings

  • Armistice Capital, LLC

    8.41%

  • Renaissance Technologies Corp

    0.83%

  • BlackRock Inc

    0.74%

  • Geode Capital Management, LLC

    0.63%

  • Vanguard Group Inc

    0.39%

  • State Street Corporation

    0.14%

Company Information

trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.

Organization
Trevena Inc
Employees
23
CEO
Ms. Carrie L. Bourdow
Industry
Health Technology

Discover More

FAQs